|
AXSM | Axsome Therapeutics, Inc. |
|
|
AXSM | Axsome Therapeutics, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.02 |
| Leverage | 83.45% |
| Market Cap | $ 4.5B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -307.7m |
| Margin | -91.69% |
Axsome Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new therapies for central nervous system (CNS) disorders in the United States. The company is headquartered in New York, New York.